ASH Conference Coverage
Featured Articles
(ASH) June 21, 2017 - Antibody PF-06747143 both attacks AML tumor cells and moves them from the nurturing bone marrow environment into the peripheral blood streams, where they are more vulnerable.
Read Article
(MedPage Today) Dec 8, 2016 - Two-thirds of patients with proteasome inhibitor-refractory myeloma responded to the antiretroviral agent nelfinavir, added to standard myeloma agents, according to a small study reported here.
Read Article
Latest Articles
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
December 07, 2016
View More
News Commentary
There is no ASH Conference Coverage commentary.

OBR Blog
By Lynne Lederman, PhD At this past December’s American Society of Hematology (ASH) annual meeting, the late-breaking... Read more
January 17, 2017
Introduction Presenting you with timely market feedback from the 58th ASH Annual Meeting held in December 2016, OBR and... Read more
January 17, 2017